Identification of potential complementary serum biomarkers to differentiate prostate cancer from benign prostatic hyperplasia using gel‐ and lectin‐based proteomics analyses

Diagnosis of prostate cancer (PCa) is currently much reliant on the invasive and time‐consuming transrectal ultrasound‐guided biopsy of the prostate gland, particularly in light of the inefficient use of prostate‐specific antigen as its biomarker. In the present study, we have profiled the sera of p...

Full description

Saved in:
Bibliographic Details
Published in:Electrophoresis 2012-07, Vol.33 (12), p.1855-1862
Main Authors: Jayapalan, Jaime J., Ng, Keng L., Razack, Azad H. A., Hashim, Onn H.
Format: Article
Language:English
Subjects:
Aged
Apolipoprotein A-II
Benign
Benign prostatic hyperplasia
Biomarker
biomarkers
Biomarkers, Tumor - blood
Biomarkers, Tumor - chemistry
Biopsy
Blood Proteins - analysis
Blood Proteins - chemistry
Blood Proteins - metabolism
Complement component C3
Data processing
Diagnosis, Differential
Electrophoresis, Gel, Two-Dimensional
Glycoproteins - blood
Glycoproteins - chemistry
Glycoproteins - metabolism
Humans
Hyperplasia
Invasiveness
kininogens
Lectin
Lectins - metabolism
Light chains
Male
Middle Aged
Prostate cancer
prostate-specific antigen
Prostatic Hyperplasia - blood
Prostatic Neoplasms - blood
Proteomics
Proteomics - methods
Serum proteins
Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
Therapeutic applications
transthyretin
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Diagnosis of prostate cancer (PCa) is currently much reliant on the invasive and time‐consuming transrectal ultrasound‐guided biopsy of the prostate gland, particularly in light of the inefficient use of prostate‐specific antigen as its biomarker. In the present study, we have profiled the sera of patients with PCa and benign prostatic hyperplasia (BPH) using the gel‐ and lectin‐based proteomics methods and demonstrated the significant differential expression of apolipoprotein AII, complement C3 beta chain fragment, inter‐alpha‐trypsin inhibitor heavy chain 4 fragment, transthyretin, alpha‐1‐antitrypsin, and high molecular weight kininogen (light chain) between the two groups of patients’ samples. Our data are suggestive of the potential use of the serum proteins as complementary biomarkers to effectively discriminate PCa from BPH, although this requires further extensive validation on clinically representative populations.
ISSN:0173-0835
1862-8346
1522-2683
DOI:10.1002/elps.201100608